Home » Stocks » CABA

Cabaletta Bio, Inc. (CABA)

Stock Price: $9.57 USD 0.38 (4.13%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 238.56M
Revenue (ttm) n/a
Net Income (ttm) -35.56M
Shares Out 24.93M
EPS (ttm) -10.97
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $9.57
Previous Close $9.19
Change ($) 0.38
Change (%) 4.13%
Day's Open 9.27
Day's Range 9.26 - 10.16
Day's Volume 41,052
52-Week Range 6.35 - 16.38

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Cabaletta Bio Inc (NASDAQ: CABA) has announced acute safety data from the first dose cohort of the ongoing DesCAARTes Phase 1 trial of DSG3-CAART for mucosal-dominant pemphigus Vulgaris (mPV). In the fi...

6 days ago - Benzinga

– Acute safety data from the first cohort in the DesCAARTes™ trial announced today; no dose limiting toxicities (DLTs) or clinically relevant adverse events observed in the first dose cohort as of April...

6 days ago - GlobeNewsWire

– No dose limiting toxicities (DLTs) or clinically relevant adverse events observed in the first dose cohort as of April 30, 2021 –

6 days ago - GlobeNewsWire

PHILADELPHIA, April 07, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for pa...

1 month ago - GlobeNewsWire

PHILADELPHIA, March 16, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for pa...

1 month ago - GlobeNewsWire

Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like UFP Industries (UFPI), Cabaletta Bio (CABA), Alto (PEIX), Ribbon (RBBN) and Software Acquisition...

Other stocks mentioned: CURI, PEIX, RBBN, UFPI
3 months ago - Zacks Investment Research

Cabaletta Bio, Inc. is a clinical-stage biotechnology company aiming to develop engineered T-cell therapies for B-cell-mediated autoimmune diseases. Cabaletta has 3 potential therapeutics from its thera...

3 months ago - Seeking Alpha

First patient ever infused with a CAAR (chimeric autoantibody receptor) T cell therapy product candidate expands the potential clinical application of CAR T technology beyond cancer into autoimmune dise...

5 months ago - GlobeNewsWire

PHILADELPHIA, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for pat...

5 months ago - GlobeNewsWire

PHILADELPHIA, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for pat...

5 months ago - GlobeNewsWire

PHILADELPHIA, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for ...

7 months ago - GlobeNewsWire

PHILADELPHIA, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for p...

8 months ago - GlobeNewsWire

PHILADELPHIA, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for p...

9 months ago - GlobeNewsWire

PHILADELPHIA and DENVER, July 07, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell ther...

10 months ago - GlobeNewsWire

Cabaletta Bio, Inc. (CABA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

11 months ago - Zacks Investment Research

Collaboration deepens pipeline with CAAR design and optimization effort in three additional B cell-mediated autoimmune diseases

11 months ago - GlobeNewsWire

PHILADELPHIA, May 12, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for pa...

11 months ago - GlobeNewsWire

Cabaletta Bio: Curative Medicines For Autoimmunity

1 year ago - Seeking Alpha

Cabaletta Bio, Inc. (CABA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

1 year ago - Zacks Investment Research

Cabaletta Bio Inc. shares slid 18% in their trading debut Friday, after underwriters priced the deal at $11, a full $3 below the $14 to $16 price range.

1 year ago - Market Watch

About CABA

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune b... [Read more...]

Industry
Biotechnology
IPO Date
Oct 25, 2019
Stock Exchange
NASDAQ
Ticker Symbol
CABA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for Cabaletta Bio stock is "Strong Buy." The 12-month stock price forecast is 22.75, which is an increase of 137.72% from the latest price.

Price Target
$22.75
(137.72% upside)
Analyst Consensus: Strong Buy